TTLTicker Tales
NSE: ZYDUSLIFEHealthcare

Zydus Lifesciences

Zydus Lifesciences is a diversified Indian pharma company that makes generic and branded medicines, consumer wellness products and biosimilars, and is now trying to get its own in-house drug (saroglitazar) approved and sold in the US.

₹1,197.90▲+28.0%1 yearClosing price, 6 Nov 2026
  • P/E ~26x
  • Q2 profit fell 27% YoY
  • Zero promoter pledge
  • FDA call due 27 Nov
  • Net debt/equity 0.16x

Updated on 7 Nov 2026 · Data as of 6 Nov 2026

Get this report as a PDF free, straight to your inbox.

Snapshot

Share price
₹1,197.90
6 Nov 2026
52-week range
₹859.83 – ₹1,245.50
All-time peak
₹1,285.01
9 Aug 2024 · −6.8% from peak
Dividend yield
0.08%
Price history since
2000
About 26 years of prices
52-week low ₹859.83high ₹1,245.50

What's happening

The single most time-sensitive item: the US FDA is due to rule on saroglitazar for primary biliary cholangitis around 27 November 2026 (Priority Review), under three weeks from today. Separately, results for the quarter ended September 2026 were reported on 3-4 November 2026: revenue rose 29% YoY to about ₹7,910 crore, but EBITDA fell 6% and net profit fell roughly 27% YoY to about ₹925 crore, and the stock dropped about 4% on the day. Management attributed the margin hit largely to stepped-up commercial spend ahead of the planned US saroglitazar launch.

In plain terms

Sales are growing solidly and broadly - across India, the US and other international markets - so this isn't a demand problem. But profit fell because the company is spending heavily now (R&D plus an estimated $100 million/year in commercial build-out) to get ready for a US launch of its own drug, saroglitazar, pending an FDA decision later this month. The tension: you're paying today's price for a business whose near-term profit is being deliberately suppressed by a bet that hasn't yet paid off. If the FDA says no or delays, that spend looks like a drag with no offsetting payoff for longer.

Quarters

Revenue growth has been consistently strong and broad-based this quarter: India formulations +18% YoY, North America formulations +21% YoY (+7% QoQ), international markets +33% YoY. But EBITDA margin compressed sharply to about 24% from roughly 33% a year earlier, and net profit fell ~27% YoY even though revenue rose 29% - a profitability squeeze, not a demand problem. Management said margin would be closer to ~25.5% if saroglitazar launch-related spend were excluded; treat that adjusted number as a management estimate, not an audited figure. R&D spend was ₹657 crore, 8.3% of revenue.

Performance

Heads-up on splits: Zydus Lifesciences has split its shares or issued bonus shares before (most recently 5-for-1 on 6 Oct 2015 and ×1.5 on 5 Apr 2010). A sudden price drop around a split date is usually just the price adjusting for the extra shares, not a crash.

Share price

+28.0% over 1 year

Returns by period

PeriodZydus LifesciencesNifty 50LUPIN
3 months+7.5%+1.9%−15.9%
1 year+28.0%−1.9%+2.4%
3 years+103.5%+29.0%+70.1%
5 years+149.9%+38.5%+120.1%

₹100 invested on 8 Nov 2021 became…

  • Zydus Lifesciences₹250
  • Nifty 50₹139
  • LUPIN₹220

Shareholder returns have been strong and broad-based: +28% over 1 year (vs Nifty -1.9%, peer Lupin +2.4%), +104% over 3 years (vs Nifty +29%, peer +70%), and +150% over 5 years (vs Nifty +39%, peer +120%). The stock is only 6.8% below its August 2024 peak and is not at either 52-week extreme. There has been no demerger or spin-off in this stock's history - only two stock splits (2010, 2015) which are already reflected in the adjusted price series - so none of this return history needs a corporate-action adjustment.

Dividend

Paid in the last 12 months

₹1.00 per share

Dividend yield

0.08%

Dividend yield is the last 12 months of dividends divided by today's share price. A 0.1% yield means every ₹100 of Zydus Lifesciences shares paid about ₹0.1 in dividends over the past year. Past payouts can change.

Recent dividends

DatePer share
24 Jul 2026₹1.00
25 Jul 2025₹11.00
26 Jul 2024₹3.00
28 Jul 2023₹6.00
28 Jul 2022₹2.50
28 Jul 2021₹3.50
23 Mar 2020₹3.50
25 Jul 2019₹3.50

Valuation

Trading around 26x trailing earnings with ROE and ROCE both near 21%. Why it looks the way it does: the market is pricing in both the steady, diversified base business and the optionality of a US saroglitazar approval - a binary event due within weeks. Whether that's cheap or expensive depends entirely on that FDA outcome: pay for it now and you're buying the option along with the business; if it fails, the multiple is supported only by the base generics/consumer business, which would look less cheap on current profit numbers.

Growth

This is volume-led, broad-based growth - all three major geographies (India, North America, international) grew double digits to 33% YoY this quarter - not a single-segment or price-led story. The margin decline is not from commodity cost pressure or competitive pricing; it's from a deliberate step-up in R&D and commercialization spend ahead of a product launch, which is a different (and more reversible) kind of margin pressure than one caused by eroding pricing power.

Health

Leverage is low: net debt/equity was about 0.16x and net debt/EBITDA about 0.50x as of the last full year, per the company's own disclosures - this is not a balance-sheet-risk story. The live risk is business/execution risk: whether the saroglitazar bet converts spend into approved, sellable revenue. Not verified - check Screener or the latest annual report for operating cash flow versus PAT conversion to confirm cash generation is keeping pace with reported profit.

Ownership

Promoters hold about 75% of the company, with zero shares pledged as of the latest filings - no leverage-driven forced-selling risk from the promoter side. Institutional holding is modest: FIIs ~7%, DIIs ~11%. No well-known individual or marquee investor appears on the public shareholding register - worth saying plainly since none is involved here.

The View

The one thing to watch

The FDA's decision on saroglitazar for primary biliary cholangitis, expected around 27 November 2026 - approval would start to justify the margin compression and spend of the last several quarters; a rejection or delay would leave that spend without a near-term payoff.

Strengths

  • +Revenue growth broad-based across geographies: India formulations +18% YoY, North America +21% YoY, international markets +33% YoY (quarter ended Sep 2026)
  • +Conservative balance sheet: net debt/equity ~0.16x and net debt/EBITDA ~0.50x
  • +Zero promoter pledge on a ~75% promoter stake
  • +5-year shareholder return of 149.92% versus Nifty's 38.53% and peer Lupin's 120.08%

Watchpoints

  • !EBITDA margin fell from ~33% to ~24% YoY this quarter, and net profit fell ~27% YoY despite 29% revenue growth
  • !FY26 final dividend was cut to ₹1/share from ₹11/share the prior year - too volatile to view this as a dividend-income stock
  • !US FDA decision on saroglitazar (PBC) expected around 27 November 2026 is an unresolved, binary catalyst priced into the stock
  • !Commercial build-out spend of an estimated $100 million/year for a US launch is a real cash commitment ahead of any confirmed approval

How sure are we about the data? · Moderate

Revenue (~₹7,910 cr), EBITDA (~₹1,895 cr) and net profit (~₹925 cr) for the quarter ended September 2026 are corroborated across multiple independent sources (Business Standard, Social News XYZ, Investing.com, Taxguru). One screener.in snapshot showed different quarterly figures (revenue ₹8,017 cr, profit ₹1,011 cr) labelled 'Q2 FY2026' - likely a stale or differently-dated cache - and was set aside as the outlier in favour of the more numerous, mutually consistent sources. Net debt/equity (0.16x) is the company's own reported figure, preferred over a cruder gross-borrowings read from a third-party aggregator. Dividend history and promoter pledge figures were corroborated across two independent sources each. Could not independently verify operating cash flow conversion - check Screener directly.

Keep it for later

Get the Zydus Lifesciences report as a PDF

The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.

Free. We use your email only to send this report and the newsletter.

Share this X LinkedIn WhatsApp

← All Nifty 100 companies

Reports are refreshed every quarter, about three days after each company announces its results.

Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 6 Nov 2026.